Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)

NCT00234143 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

360

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

BEHAVIORAL: Darbepoetin and Filgrastim
DRUG: Darbepoetin

Sponsor

St. Bartholomew's Hospital